These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

249 related items for PubMed ID: 15945505

  • 1. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
    Stöhr W, Langer T, Kremers A, Bielack S, Lamprecht-Dinnesen A, Frey E, Beck JD, German Late Effects Working Group in the German Society of Pediatric Oncology and Hematology.
    Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
    [Abstract] [Full Text] [Related]

  • 2. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW, van den Berg H, van Dalen EC.
    Cochrane Database Syst Rev; 2012 May 16; (5):CD009219. PubMed ID: 22592737
    [Abstract] [Full Text] [Related]

  • 3. Ototoxicity in children treated for osteosarcoma.
    Lewis MJ, DuBois SG, Fligor B, Li X, Goorin A, Grier HE.
    Pediatr Blood Cancer; 2009 Mar 16; 52(3):387-91. PubMed ID: 19061216
    [Abstract] [Full Text] [Related]

  • 4. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
    Vos HI, Guchelaar HJ, Gelderblom H, de Bont ES, Kremer LC, Naber AM, Hakobjan MH, van der Graaf WT, Coenen MJ, te Loo DM.
    Pharmacogenet Genomics; 2016 May 16; 26(5):243-7. PubMed ID: 26928270
    [Abstract] [Full Text] [Related]

  • 5. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
    Fox E, Levin K, Zhu Y, Segers B, Balamuth N, Womer R, Bagatell R, Balis F.
    Oncologist; 2018 Jul 16; 23(7):762-e79. PubMed ID: 29445029
    [Abstract] [Full Text] [Related]

  • 6. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
    Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ, van Grotel M, van den Heuvel-Eibrink MM, DCOG-LATER, The Netherlands.
    Eur J Cancer; 2016 Dec 16; 69():77-85. PubMed ID: 27821322
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
    Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J.
    Pediatr Blood Cancer; 2012 Jul 15; 59(1):144-8. PubMed ID: 22431292
    [Abstract] [Full Text] [Related]

  • 8. Ototoxicity from cisplatin therapy in childhood cancer.
    Coradini PP, Cigana L, Selistre SG, Rosito LS, Brunetto AL.
    J Pediatr Hematol Oncol; 2007 Jun 15; 29(6):355-60. PubMed ID: 17551394
    [Abstract] [Full Text] [Related]

  • 9. Hearing function in soft tissue sarcoma patients after treatment with carboplatin: a report from the Late Effects Surveillance System.
    Stöhr W, Langer T, Kremers A, Brecht I, Treuner J, Dinnesen A, Beck JD.
    Oncol Rep; 2004 Oct 15; 12(4):767-71. PubMed ID: 15375498
    [Abstract] [Full Text] [Related]

  • 10. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C, Krefeld B, Dinnesen AG, Deuster D, Seifert E, Würthwein G, Jaehde U, Pieck AC, Boos J.
    Pediatr Blood Cancer; 2006 Aug 15; 47(2):183-93. PubMed ID: 16302218
    [Abstract] [Full Text] [Related]

  • 11. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
    Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG.
    HNO; 2007 Apr 15; 55(4):299-306. PubMed ID: 16437215
    [Abstract] [Full Text] [Related]

  • 12. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
    Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, Ross CJD, Wright M, Mena V, Rushing T, Esbenshade AJ, Carleton BC, Orgel E.
    Lancet Child Adolesc Health; 2021 Apr 15; 5(4):274-283. PubMed ID: 33581749
    [Abstract] [Full Text] [Related]

  • 13. Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma.
    Lafay-Cousin L, Purdy E, Huang A, Cushing SL, Papaioannou V, Nettel-Aguirre A, Bouffet E.
    Pediatr Blood Cancer; 2013 Feb 15; 60(2):287-92. PubMed ID: 23002030
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
    Sriyapai T, Thongyai K, Phuakpet K, Vathana N, Buaboonnam J, Sanpakit K.
    Turk J Pediatr; 2022 Feb 15; 64(3):531-541. PubMed ID: 35899566
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Recovery from cisplatin-induced ototoxicity: a case report and review.
    Truong MT, Winzelberg J, Chang KW.
    Int J Pediatr Otorhinolaryngol; 2007 Oct 15; 71(10):1631-8. PubMed ID: 17706797
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
    Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I.
    Oncology; 2006 Oct 15; 70(3):177-84. PubMed ID: 16757924
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.